All News

An analysis of adoption of and adherence to chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in the primary care setting unearthed disappointing results, finding suboptimal use of pulmonary function tests, no routine use of validated symptoms scales for diagnosis, and variation in pharmacotherapy.

Witnesses appearing before the Senate Judiciary Committee discussed the need to maintain innovation for new drug discoveries while ensuring patients have access to treatments for chronic diseases as well as potentially curative therapies. In addition, Senator John Cornyn, R-Texas, raised the idea of giving the Federal Trade Commission (FTC) more authority to cut through patent thickets; his office said later he will propose a bill doing just that.

Federal prosecutors have reached a $17 million settlement with Acadia after Medicaid fraud allegations; rates of heart failure–related deaths are on the rise among adults between 35 and 64 years old; the FDA has asked manufacturers of sunscreen to review the safety of the chemicals used in their products after a new study found that many of the ingredients in sunscreen may be absorbed into the bloodstream upon use.

The FDA approved Pfizer’s transthyretin stabilizer tafamidis, the first treatment for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), a rare, incurable disease. Pfizer will sell the oral drugs under the names Vyndaqel and Vyndamax.

Parkinson disease (PD) is the second most common neurodegenerative disorder found in the elderly, currently affecting an estimated 2% of individuals 60 years or older. PD is a multifactorial disease in which both environmental and genetic factors are significantly associated with disease onset. Although symptoms of the disease may present with a tremor or perhaps a speech problem, by the time the symptoms are evident, it is often too late to stop the progression of the disease.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text